Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion won in cumulative sales as of...
Search results for "product approval"
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they have selected the "2026 Health...
Celltrion Secures Historic FDA Interchangeability Status for Truxima
Celltrion announced on the 1st that the U.S. Food and Drug Administration has granted interchangeable status to Truxima...
Fueling the Future of Biohealth: InterBiz Forum Opens in Jeju With a Record 1,500 Tech Deals
The 24th InterBiz Bio Partnering & Investment Forum 2026, a premier biohealth technology deal-making event, opened...
Dongkook Pharmaceutical Secures 39 Billion Won Latin American Export Deal for BPH Treatment Uresco
Waking up frequently at night to urinate or noticing a weaker urine stream is a common health concern for men as they...
Rznomics Secures U.S. Patent for Alzheimer’s RNA Therapy Candidate RZ-003
Rznomics, a biopharmaceutical company specializing in RNA-based gene therapies, announced on the 24th that it has...
GC Wellbeing’s Laennec Injection Clears Phase 3 Hurdle for IV Drip Use, Boosting Growth Prospects
GC Wellbeing announced on June 16 that it has secured topline results demonstrating that its chronic liver disease...
Ebola spreads rapidly in DRC—how far have new vaccines and treatments come?
A Reuters report said the U.K. media outlet The Guardian reported on the 19th (20th in Korea time) that the World...
Celltrion to Acquire French Healthcare Specialist Gifrer, Eyeing European Pharmacy Market
Celltrion announced on the 12th its acquisition of Gifrer, a French healthcare specialist with a 114-year history.
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?
A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...